

Ana Garcia-Osta

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/634869/ana-garcia-osta-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51
papers

2,735
citations

27
h-index

52
g-index

52
ext. papers

3,084
ext. citations

6.5
avg, IF

4.83
L-index

#	Paper	IF	Citations
51	Amyloid-Driven Tau Accumulation on Mitochondria Potentially Leads to Cognitive Deterioration in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
50	Identifying the Main Functional Pathways Associated with Cognitive Resilience to Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
49	PLA2G4E, a candidate gene for resilience in Alzheimer's disease and a new target for dementia treatment. <i>Progress in Neurobiology</i> , 2020 , 191, 101818	10.9	9
48	Linking histone deacetylases and phosphodiesterase 5 in novel treatments for Alzheimer's disease 2020 , 213-226		
47	GLUT12 Expression in Brain of Mouse Models of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2020 , 57, 798-805	6.2	8
46	Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 4076-4101	5.7	18
45	Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2019 , 16, 26-37	10.7	43
44	Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 149	5.3	21
43	Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 1765-1782	5.7	18
42	Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples. <i>Neurotherapeutics</i> , 2018 , 15, 742-750	6.4	5
41	The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma. <i>Neuro-Oncology</i> , 2018 , 20, 930-941	1	13
40	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2018 , 150, 506-524	6.8	35
39	Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice. <i>Frontiers in Immunology</i> , 2018 , 9, 68	8.4	11
38	Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2017 , 8, 638-661	5.7	26
37	A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice. <i>Neuropsychopharmacology</i> , 2017 , 42, 524-539	8.7	65
36	Chronic Mild Stress Assay Leading to Early Onset and Propagation of Alzheimer's Disease Phenotype in Mouse Models. <i>Methods in Molecular Biology</i> , 2016 , 1303, 241-6	1.4	10
35	Advanced Assay Monitoring APP-Carboxyl-Terminal Fragments as Markers of APP Processing in Alzheimer Disease Mouse Models. <i>Methods in Molecular Biology</i> , 2016 , 1303, 117-23	1.4	5

34	Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels. <i>Journal of Neurochemistry</i> , 2016 , 136, 403-15	6	31
33	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 8967-9004	8.3	59
32	Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition. <i>Mediators of Inflammation</i> , 2015 , 2015, 940207	4.3	55
31	Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease. <i>Clinical Epigenetics</i> , 2015 , 7, 108	7.7	39
30	Decreased levels of guanosine 3',5'-cyclic monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2015 , 41, 471-82	5.2	65
29	Phosphodiesterase inhibition in cognitive decline. <i>Journal of Alzheimer's Disease</i> , 2014 , 42 Suppl 4, S561-73	7.3	21
28	Synthesis and evaluation of (13)N-labelled azo compounds for amyloid imaging in mice. <i>Molecular Imaging and Biology</i> , 2014 , 16, 538-49	3.8	14
27	Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. <i>EMBO Molecular Medicine</i> , 2014 , 6, 1246-62	12	84
26	Current animal models of Alzheimer's disease: challenges in translational research. <i>Frontiers in Neurology</i> , 2014 , 5, 182	4.1	20
25	Epigenetic drugs in Alzheimer's disease. <i>Biomolecular Concepts</i> , 2013 , 4, 433-45	3.7	26
24	Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. <i>Neuropharmacology</i> , 2013 , 64, 114-23	5.5	109
23	Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer's disease-like phenotype of a commonly used mouse model. <i>Current Pharmaceutical Design</i> , 2013 , 19, 5076-84	3.3	42
22	Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. <i>Hippocampus</i> , 2012 , 22, 1040-50	3.5	173
21	Phosphodiesterases as therapeutic targets for Alzheimer's disease. <i>ACS Chemical Neuroscience</i> , 2012 , 3, 832-44	5.7	180
20	Chronic mild stress accelerates the onset and progression of the Alzheimer's disease phenotype in Tg2576 mice. <i>Journal of Alzheimer's Disease</i> , 2012 , 28, 567-78	4.3	44
19	Dysregulated postsynaptic density and endocytic zone in the amygdala of human heroin and cocaine abusers. <i>Biological Psychiatry</i> , 2011 , 69, 245-52	7.9	30
18	Chronic mild stress in mice promotes cognitive impairment and CDK5-dependent tau hyperphosphorylation. <i>Behavioural Brain Research</i> , 2011 , 220, 338-43	3.4	34
17	Long-term phenylbutyrate administration prevents memory deficits in Tg2576 mice by decreasing Abeta. <i>Frontiers in Bioscience - Elite</i> , 2011 , 3, 1375-84	1.6	23

16	Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease. <i>Current Medicinal Chemistry</i> , 2011 , 18, 5545-53	4.3	20
15	Sildenafil restores cognitive function without affecting amyloid burden in a mouse model of Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2011 , 164, 2029-41	8.6	129
14	A critical role for IGF-II in memory consolidation and enhancement. <i>Nature</i> , 2011 , 469, 491-7	50.4	306
13	Disrupting the memory of places induced by drugs of abuse weakens motivational withdrawal in a context-dependent manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 12345-50	11.5	38
12	Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. <i>Neuropsychopharmacology</i> , 2010 , 35, 1593-604	8.7	167
11	Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. <i>Neurobiology of Disease</i> , 2010 , 38, 237-45	7.5	60
10	Amyloid beta mediates memory formation. <i>Learning and Memory</i> , 2009 , 16, 267-72	2.8	119
9	Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. <i>Neuropsychopharmacology</i> , 2009 , 34, 1721-32	8.7	304
8	MuSK expressed in the brain mediates cholinergic responses, synaptic plasticity, and memory formation. <i>Journal of Neuroscience</i> , 2006 , 26, 7919-32	6.6	69
7	Increased CRE-binding activity and tryptophan hydroxylase mRNA expression induced by 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in the rat frontal cortex but not in the hippocampus. <i>Molecular Brain Research</i> , 2004 , 126, 181-7		20
6	Reduced basal and phencyclidine-induced expression of heat shock protein-70 in rat prefrontal cortex by the atypical antipsychotic abaperidone. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003 , 27, 31-6	5.5	5
5	BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons. <i>NeuroReport</i> , 2001 , 12, 919-23	1.7	65
4	Effect of p-chloroamphetamine on 5-HT _{1A} and 5-HT ₇ serotonin receptor expression in rat brain. <i>Journal of Neurochemistry</i> , 2000 , 74, 1790-7	6	7
3	Implanted BDNF-producing fibroblasts prevent neurotoxin-induced serotonergic denervation in the rat striatum. <i>Molecular Brain Research</i> , 2000 , 76, 306-14		16
2	Facilitation by 8-OH-DPAT of passive avoidance performance in rats after inactivation of 5-HT _{1A} receptors. <i>British Journal of Pharmacology</i> , 1999 , 128, 1691-8	8.6	28
1	Differential regulation by methylenedioxymethamphetamine of 5-hydroxytryptamine _{1A} receptor density and mRNA expression in rat hippocampus, frontal cortex, and brainstem: the role of corticosteroids. <i>Journal of Neurochemistry</i> , 1997 , 68, 1099-105	6	42